Journal article

Radioimmunotherapy with alpha-particle - Emitting Bi-213-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy

Marcus P Kelly, Fook T Lee, Kiki Tahtis, Fiona E Smyth, Martin W Brechbiel, Andrew M Scott

CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2007

Abstract

PURPOSE: Previous experience in solid tumor radioimmunotherapy studies has indicated that greatest therapeutic efficacy is achieved in the treatment of small-volume disease. alpha-Particle-emitting radioisotopes possess several physical characteristics ideally suited to the treatment of minimal residual disease. Therefore, we have investigated the efficacy of the alpha-particle-emitting bismuth-213 (213Bi) radioimmunotherapy using the humanized anti-Lewis Y (Ley) monoclonal antibody humanized 3S193 (hu3S193). EXPERIMENTAL DESIGN: The intracellular localization of hu3S193 in Ley-positive MCF-7 breast carcinoma cells was assessed by confocal microscopy. Cytotoxicity of 213Bi-hu3S193 and apopto..

View full abstract

University of Melbourne Researchers